Stage IV/Metastatic Bladder Cancer


Keytruda Immunotherapy Improves Overall Survival in Bladder Cancer (November 10, 2016)

Bladder cancer will be diagnosed in approximately 77,000 people in the United States this year alone. The average age that patients are diagnosed with bladder cancer is 70 years, with 80% of these patients... Continue Reading

Tecentriq® Approved for Bladder Cancer (June 8, 2016)

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor,... Continue Reading

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer (June 8, 2016)

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy.... Continue Reading

Durvalumab Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients with PD-L1 Positive Urothelial Bladder Cancer (February 19, 2016)

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death ligand-1... Continue Reading

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (March 16, 2015)

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment.... Continue Reading

Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)

Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014... Continue Reading

Experimental Drug Shows Promise for Treatment of Metastatic Bladder Cancer (June 12, 2014)

According to results of a Phase I trial presented at the 2014 annual meeting of the American Society of Clinical Oncology, an investigative drug, MPDL3280A, demonstrates promise for the treatment of PD-L1... Continue Reading

Strategies to Improve Treatment (November 22, 2013)

The progress that has been made in the treatment of bladder cancer has resulted from improved treatments evaluated in clinical trials. Future progress in the treatment of bladder cancer will result from... Continue Reading

Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)

Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a... Continue Reading

Factors Affecting Quality of Life at the End of Life (July 20, 2012)

For people with advanced cancer, quality of life at the end of life—sometimes referred to as “a good death”—may have less to do with medical treatment and more to do with a therapeutic alliance... Continue Reading

Adding Chemotherapy to Radiation Reduces Bladder Cancer Recurrence (April 30, 2012)

Chemotherapy plus radiation reduces the risk of recurrence in muscle-invasive bladder cancer patients by nearly 50% compared to radiation alone, according to the results of a study published in the New... Continue Reading

Liposomal Cisplatin Safe for Patients with Renal Insufficiency (June 14, 2011)

Liposomal cisplatin (Nanoplatin®), a chemotherapy drug still in clinical trials, does not cause damage to the kidneys and appears to provide at least equal anti-cancer effects as cisplatin (Platinol®)... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival... Continue Reading

Cancer Caregivers Devote Substantial Time and Effort (September 9, 2009)

On average, informal caregivers of cancer patients devote more than eight hours per day to caregiving. These results were published in Cancer. Informal caregiving is an important part of cancer management.... Continue Reading

Update on the Management of Genitourinary Malignancies (October 12, 2007)

Update on the Management of Genitourinary Malignancies: A Report from the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO) Kidney cancer, the orphan disease that had only one approved... Continue Reading

Herceptin® Evaluated in Advanced Bladder Cancer (July 16, 2007)

Herceptin® Evaluated in Advanced Bladder Cancer According to the results of a Phase II clinical trial, Herceptin® (trastuzumab)-a targeted therapy used in the treatment of HER2-positive breast cancer-may... Continue Reading

Gemzar® and Eloxatin® Promising for Advanced Bladder Cancer (August 21, 2006)

Gemzar® and Eloxatin® Promising for Advanced Bladder Cancer According to an article recently published in the Annals of Oncology, the chemotherapy combination consisting of Eloxatin® (oxaliplatin) and... Continue Reading

High-Volume Hospitals Offer Better Outcomes After Radical Cystectomy and Radical Prostatectomy (May 8, 2006)

High-Volume Hospitals Offer Better Outcomes After Radical Cystectomy and Radical Prostatectomy Among patients undergoing radical cystectomy (removal of bladder) or radical prostatectomy (removal of prostate),... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS